Attracting 60,000 Adalimumab Patients Aids Biogen

Biogen’s Total Year-To-Date Biosimilar Sales Top $500m

 
• By Aidan Fry
  
60000
Biogen says around 60,000 patients are now taking its Imraldi adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products